Search
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalChloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. … Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential.
Arbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in … diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately .
Categories: Compounds used in a research, industrial, or household settingMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … [L1118] It was never approved by the FDA.
Lomitapide
go.drugbank.com/drugs/DB08827Approved[A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity. … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: JUXTAPID® CÁPSULAS POR 20 MG, JUXTAPID® CÁPSULAS POR 5 MGParoxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.
Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePlazomicin
go.drugbank.com/drugs/DB12615ApprovedIt was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy [A33942]. … On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseClonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigational[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history … Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year.
Synonyms: 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-oneProducts: Co ClonazepamCarbinoxamine
go.drugbank.com/drugs/DB00748ApprovedThe product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many … This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Categories: Antihistamines for Systemic UseSecretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalThe main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … It is indicated for the stimulation of the pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma, and facilitate the identification
Categories: Tests for Pancreatic FunctionMargetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab]. … Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative